Skip to main content
SpringerLink
Log in

Subcutaneous implantation of microencapsulated cells overexpressing α-L-iduronidase for mucopolysaccharidosis type I treatment

  • Clinical Applications of Biomaterials
  • Original Research
  • Published:
Journal of Materials Science: Materials in Medicine Aims and scope Submit manuscript

Abstract

Mucopolysaccharidosis type I (MPS I) is caused by a deficiency of α-L-iduronidase (IDUA), resulting in accumulation of glycosaminoglycans (GAG) in lysosomes. Microencapsulation of recombinant cells is a promising gene/cell therapy approach that could overcome the limitations of the current available treatments. In the present study we produced alginate-poly-L-lysine-alginate (APA) microcapsules containing recombinant cells overexpressing IDUA, which were implanted in the subcutaneous space of MPS I mice in order to evaluate their potential effect as a treatment for this disease. APA microcapsules enclosing genetically modified Baby Hamster Kidney cells overexpressing IDUA were produced and implanted in the subcutaneous space of 4-month-old MPS I mice (Idua -/-). Treatment was performed using two cell concentrations: 8.3 × 107 and 8.3 × 106 cells/mL. Untreated MPS I and normal mice were used as controls. Microcapsules were retrieved and analyzed after treatment. Increased IDUA in the liver, kidney and heart was detected 24 h postimplantation. After 120 days, higher IDUA activity was detected in the liver, kidney and heart, in both groups, whereas GAG accumulation was reduced only in the high cell concentration group. Microcapsules analysis showed blood vessels around them, as well as inflammatory cells and a fibrotic layer. Microencapsulated cells were able to ameliorate some aspects of the disease, indicating their potential as a treatment. To achieve better performance of the microcapsules, improvements such as the modulation of inflammatory response are suggested.

Graphical Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Abbreviations

APA:

Alginate-poly-L-lysine-alginate

ERT:

Enzyme replacement therapy

GAG:

Glycosaminoglycans

HSCT:

Hematopoietic stem cell transplantation

IDUA:

Alpha-L-iduronidase

LSD:

Lysosomal storage disorder

MPS I:

Mucopolysaccharidosis type I

rBHKIdua :

Recombinant BHK to overexpress IDUA

References

  1. Wraith JE, Jones S. Mucopolysaccharidosis type I. Pediatr Endocrinol Rev. 2014;12(Suppl 1):102–6.

    Google Scholar 

  2. Clarke La, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Longterm efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123:229–40.

    Article  Google Scholar 

  3. Giugliani R, Federhen A, Rojas MVM, Vieira T, Artigalás O, Pinto LL, et al. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet Mol Biol. 2010;33:589–604.

    Article  Google Scholar 

  4. Beck M, Arn P, Giugliani R, Muenzer J, Okuyama T, Taylor J, Fallet S. The natural history of MPS I: global perspectives from the MPS I Registry. Genet Med. 2014;16(10):759–65.

    Article  Google Scholar 

  5. Giugliani R, Federhen A, Vairo F, Vanzella C, Pasqualim G, da Silva LM, Giugliani L, de Boer AP, de Souza CF, Matte U, Baldo G. Emerging drugs for the treatment of mucopolysaccharidoses. Expert Opin Emerg Drugs. 2016;21(1):9–26.

    Article  Google Scholar 

  6. Boelens JJ, Prasad VK, Tolar J, Wynn RF, Peters C. Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr Clin North Am. 2010;57:123–45.

    Article  Google Scholar 

  7. Jameson E, Jones S, Remmington T. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I. Cochrane Database Syst Rev. 2016;1(4):CD009354.

    Google Scholar 

  8. Matte U, Lagranha VL, de Carvalho TG, Mayer FQ, Giugliani R. Cell microencapsulation: a potential tool for the treatment of neuronopathic lysosomal storage diseases. J Inherit Metab Dis. 2011;34:983–90.

    Article  Google Scholar 

  9. Giugliani R. Mucopolysacccharidoses: from understanding to treatment, acentury of discoveries. Genet Mol Biol. 2012;35(4 (Suppl)):924–31.

    Article  Google Scholar 

  10. Baldo G, Giugliani R, Matte U. Gene delivery strategies for the treatment of mucopolysaccharidoses. Expert Opin Drug Deliv. 2014;11:449–59.

    Article  Google Scholar 

  11. Noh H, Lee JI. Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther. 2014;39(3):215–24.

    Article  Google Scholar 

  12. Orive G, Tam SK, Pedraz JL, Hallé JP. Biocompatibility of alginate-poly-L-lysine microcapsules for cell therapy. Biomaterials. 2006;27(20):3691–700.

    Article  Google Scholar 

  13. Baldo G, Quoos Mayer F, Burin M, Carrillo-Farga J, Matte U, Giugliani R. Recombinant encapsulated cells overexpressing alpha-L-iduronidase correct enzyme deficiency in human mucopolysaccharidosis type I cells. Cells Tissues Organs. 2012;195:323–9.

    Article  Google Scholar 

  14. Baldo G, Mayer FQ, Martinelli B, Meyer FS, Burin M, Meurer L, et al. Intraperitoneal implant of recombinant encapsulated cells overexpressing alpha-Liduronidase partially corrects visceral pathology in mucopolysaccharidosis type I mice. Cytotherapy. 2012;14:860–7.

    Article  Google Scholar 

  15. Lagranha VL, de Carvalho TG, Giugliani R, Matte U. Treatment of MPS I mice with microencapsulated cells overexpressing IDUA: effect of the prednisolone administration. J Microencapsul. 2013;30(4):383–9.

    Article  Google Scholar 

  16. Consiglio A, Martino S, Dolcetta D, Cusella G, Conese M, Marchesini S, Benaglia G, Wrabetz L, Orlacchio A, Déglon N, Aebischer P, Severini GM, Bordignon C. Metabolic correction in oligodendrocytes derived from metachromatic leukodystrophy mouse model by using encapsulated recombinant myoblasts. J Neurol Sci. 2007;15(255(1–2)):7–16.

    Article  Google Scholar 

  17. Piller Puicher E, Tomanin R, Salvalaio M, Friso A, Hortelano G, Marin O, et al. Encapsulated engineered myoblasts can cure Hurler syndrome: preclinical experiments in the mouse model. Gene Ther. 2012;19:355–64.

    Article  Google Scholar 

  18. Paul A, Ge Y, Prakash S, Shum-Tim D. Microencapsulated stem cells for tissue repairing: implications in cell-based myocardial therapy. Regen Med. 2009;4:733–45.

    Article  Google Scholar 

  19. Blocki A, Beyer S, Dewavrin JY, Goralczyk A, Wang Y, Peh P, Ng M, Moonshi SS, Vuddagiri S, Raghunath M, Martinez EC, Bhakoo KK. Microcapsules engineered to support mesenchymal stem cell (MSC) survival and proliferation enable long-term retention of MSCs in infarcted myocardium. Biomaterials. 2015;53:12–24.

    Article  Google Scholar 

  20. Calafiore R, Basta G. Clinical application of microencapsulated islets: actual prospectives on progress and challenges. Adv Drug Deliv Rev. 2014;67-68:84–92.

    Article  Google Scholar 

  21. Song S, Roy S. Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: cells, biomaterials, and devices. Biotechnol Bioeng. 2016;113(7):1381–402.

    Article  Google Scholar 

  22. Goren A, Gilert A, Meyron‐Holtz E. Alginate encapsulated cells secreting Fasligand reduce lymphoma carcinogenicity. Cancer Sci. 2012;103:116–24.

    Article  Google Scholar 

  23. Bhunchu S, Rojsitthisak P. Biopolymeric alginate-chitosan nanoparticles as drug delivery carriers for câncer therapy. Pharmazie. 2014;69(8):563–70.

    Google Scholar 

  24. Saenz del Burgo L, Compte M, Aceves M, Hernández RM, Sanz L, Álvarez-Vallina L, Pedraz JL. Microencapsulation of therapeutic bispecific antibodies producing cells: immunotherapeutic organoids for cancer management. J Drug Target. 2015;23(2):170–9.

    Article  Google Scholar 

  25. Garcia P, Youssef I, Utvik JK, Florent-Béchard S, Barthélémy V, MalaplateArmand C, et al. Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer’s disease. J Neurosci. 2010;30:7516–27.

    Article  Google Scholar 

  26. Emerich DF, Orive G, Thanos C, Tornoe J, Wahlberg LU. Encapsulated cell therapy for neurodegenerative diseases: from promise to product. Adv Drug Deliv Rev. 2014 Apr;67–68:131–41.

    Article  Google Scholar 

  27. Mayer FQ, Baldo G, de Carvalho TG, Lagranha VL, Giugliani R, Matte U. Effects of cryopreservation and hypothermic storage on cell viability and enzyme activity in recombinant encapsulated cells overexpressing alpha-L-iduronidase. Artif Organs. 2010;34:434–9.

    Article  Google Scholar 

  28. Ohmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld EF. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA. 2003;100:1902–7.

    Article  Google Scholar 

  29. Hopwood JJ, Muller V, Smithson A, Baggett N. A fluorometric assay using 4-methylumbelliferyl alpha-L-iduronide for the estimation of alpha-L-iduronidase activity and the detection of Hurler and Scheie syndromes. Clin Chim Acta. 1979;92(2):257–65.

    Article  Google Scholar 

  30. Santos E, Zarate J, Orive G, Hernández RM, Pedraz JL. Biomaterials in cell microencapsulation. Adv Exp Med Biol. 2010;670:5–21.

    Article  Google Scholar 

  31. Vériter S, Gianello P, Dufrane D. Bioengineered sites for islet cell transplantation. Curr Diab Rep. 2013;13:745–55.

    Article  Google Scholar 

  32. Cotugno G, Tessitore A, Capalbo A, Annunziata P, Strisciuglio C, Faella A, Aurilio M, Di Tommaso M, Russo F, Mancini A, De Leonibus E, Aloj L, Auricchio A. Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses. Hum Gene Ther. 2010;21(5):555–69.

    Article  Google Scholar 

  33. Wong SP, Argyros O, Harbottle RP. Sustained expression from DNA vectors. Adv Genet. 2015;89:113–52.

    Google Scholar 

  34. Friso A, Tomanin R, Alba S, Gasparotto N, Puicher EP, Fusco M, et al. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. J Gene Med. 2005;7:1482–91.

    Article  Google Scholar 

  35. Beck M. Therapy for lysosomal storage disorders. IUBMB Life. 2010;62:33–40.

    Google Scholar 

  36. Barsoum SC, Milgram W, Mackay W, Coblentz C, Delaney KH, Kwiecien JM, Kruth SA, Chang PL. Delivery of recombinant gene product to canine brain with the use of microencapsulation. J Lab Clin Med. 2003;142(6):399–413.

    Article  Google Scholar 

  37. Ciron C, Desmaris N, Colle M-A, Raoul S, Joussemet B, Vérot L, et al. Gene therapy of the brain in the dog model of Hurler’s syndrome. Ann Neurol. 2006;60:204–13.

    Article  Google Scholar 

  38. Di Domenico C, Villani G. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector. Hum Gene Ther. 2005;90:81–90.

    Article  Google Scholar 

  39. Murua A, Castro M, de, Orive G. In vitro characterization and in vivo functionality of erythropoietin-secreting cells immobilized in alginate-poly-L-lysine-alginate microcapsules. Biomacromolecules. 2007;8:3302–7.

    Article  Google Scholar 

  40. Vériter S, Mergen J, Goebbels R-M, Aouassar N, Grégoire C, Jordan B, et al. In vivo selection of biocompatible alginates for islet encapsulation and subcutaneous transplantation. Tissue Eng Part A. 2010;16:1503–13.

    Article  Google Scholar 

  41. Tam SK, de Haan BJ, Faas MM, Hallé J-P, Yahia L, de Vos P. Adsorption of human immunoglobulin to implantable alginate-poly-L-lysine microcapsules: effect of microcapsule composition. J Biomed Mater Res A. 2009;89:609–15.

    Article  Google Scholar 

  42. Dusseault J, Tam SK, Ménard M, Polizu S, Jourdan G, Yahia L, et al. Evaluation of alginate purification methods: effect on polyphenol, endotoxin, and protein contamination. J Biomed Mater Res A. 2006;76:243–51.

    Article  Google Scholar 

  43. Rokstad AM, Lacík I, de Vos P, Strand BL. Advances in biocompatibility and physico-chemical characterization of microspheres for cell encapsulation. Adv Drug Deliv Rev. 2014;67–68:111–30.

    Article  Google Scholar 

  44. Murua A, Orive G, Hernández RM, Pedraz JL. Xenogeneic transplantation of erythropoietin-secreting cells immobilized in microcapsules using transiente immunosuppression. J Control Release. 2009;137(3):174–8.

    Article  Google Scholar 

  45. Acarregui A, Pedraz JL, Blanco FJ, Hernández RM, Orive G. Hydrogel-based scaffolds for enclosing encapsulated therapeutic cells. Biomacromolecules. 2013;14:322–30.

    Article  Google Scholar 

Download references

Acknowledgements

The authors are grateful to CNPq, CAPES and FIPE-HCPA for the financial support that allowed this research.

Author information

Author notes

    Authors and Affiliations

    1. Gene Therapy Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

      Valeska Lizzi Lagranha, Barbara Zambiasi Martinelli, Guilherme Baldo, Giuseppe Ávila Testa, Talita Giacomet de Carvalho, Roberto Giugliani & Ursula Matte

    2. Postgraduate Program in Genetics and Molecular Biology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

      Valeska Lizzi Lagranha, Guilherme Baldo, Talita Giacomet de Carvalho, Roberto Giugliani & Ursula Matte

    3. Postgraduate Program in Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

      Barbara Zambiasi Martinelli & Roberto Giugliani

    4. Postgraduate Program in Physiology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

      Guilherme Baldo

    Authors
    1. Valeska Lizzi Lagranha
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Barbara Zambiasi Martinelli
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Guilherme Baldo
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Giuseppe Ávila Testa
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Talita Giacomet de Carvalho
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Roberto Giugliani
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Ursula Matte
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Ursula Matte.

    Ethics declarations

    Conflict of interest

    The authors declare no competing conflict of interest.

    Additional information

    Valeska Lizzi Lagranha and Barbara Zambiasi Martinelli contributed equally in this article.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Lizzi Lagranha, V., Zambiasi Martinelli, B., Baldo, G. et al. Subcutaneous implantation of microencapsulated cells overexpressing α-L-iduronidase for mucopolysaccharidosis type I treatment. J Mater Sci: Mater Med 28, 43 (2017). https://doi.org/10.1007/s10856-017-5844-4

    Download citation

    • Received:

    • Accepted:

    • Published:

    • DOI: https://doi.org/10.1007/s10856-017-5844-4

    Keywords

    Search

    Navigation